Metabolic Brain Disease

, Volume 28, Issue 2, pp 313–320 | Cite as

Disaccharides in the treatment of hepatic encephalopathy

Original Paper

Abstract

Management of hepatic encephalopathy (HE) primarily involves avoidance of precipitating factors and administration of various ammonia-lowering therapies such as nonabsorbable disaccharides and antimicrobial agents like rifaximin. The nonabsorbable disaccharides which include lactulose and lactitol are considered the first-line therapy for the treatment of HE and minimal hepatic encephalopathy (MHE). Lactulose significantly improves cognitive function and health-related quality of life in patients with MHE. Lactitol is comparable to lactulose in the treatment of HE with fewer side effects. Lactulose has also shown to be effective in primary and secondary prophylaxis of HE. Disaccharides were found to be comparable to rifaximin in recent systemic reviews in the treatment of HE however conclusion was based on inclusion of some poor quality trials. Combination therapy of disaccharides either with rifaximin, L-ornithine L-aspartate,probiotics for the treatment of HE needs further validation in large studies.

Keywords

Hepatic encephalopathy Disaccharides Lactulose 

References

  1. Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 107(7):1043–1050PubMedCrossRefGoogle Scholar
  2. Albrecht J, Zielińska M, Norenberg MD (2010) Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal. Biochem Pharmacol 80(9):1303–1308PubMedCrossRefGoogle Scholar
  3. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C (2003) Branched-chain amino acids for hepatic encephalopathy Cochrane Database Syst Rev;(2):CD001939Google Scholar
  4. Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328(7447):1046PubMedCrossRefGoogle Scholar
  5. Atterbury CE, Maddrey WC, Conn HO (1978) Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 23:398–406PubMedCrossRefGoogle Scholar
  6. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K (2007) Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 102:1903–1909PubMedCrossRefGoogle Scholar
  7. Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, Gibson DP, Hoffmann RG, Stravitz RT, Heuman DM, Sterling RK, Shiffman M, Topaz A, Boyett S, Bell D, Sanyal AJ (2009a) Minimal hepatic encephalopathy is associated with motor vehicle. Hepatology 50(4):1175–1183PubMedCrossRefGoogle Scholar
  8. Bajaj JS, Wade JB, Sanyal AJ (2009b) Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 50(6):2014–2021PubMedCrossRefGoogle Scholar
  9. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071–1081PubMedCrossRefGoogle Scholar
  10. Bismuth M, Funakoshi N, Cadranel JF, Blanc P (2011) Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol 23(1):8–22PubMedCrossRefGoogle Scholar
  11. Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, Gremy F, Michel H (1992) Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 15(2):222–228PubMedCrossRefGoogle Scholar
  12. Blanc P, Couderc M, Peray P, Liautard J, Larrey D, Michel H (1993) Lactitol versus vancomycin in the treatment of acute hepatic encephalopathy: a double blind, randomized trial [abstract]. Gut 34:46CrossRefGoogle Scholar
  13. Blei AT, Cordoba J (2001) Hepatic encephalopathy. Am J Gastroenterol 96:1968–1976PubMedCrossRefGoogle Scholar
  14. Cammà C, Fiorello F, Tinè F, Marchesini G, Fabbri A, Pagliaro L (1993) Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 38(5):916–922PubMedCrossRefGoogle Scholar
  15. Clausen MR, Mortensen PB (1997) Lactulose, disaccharides and colonic flora: clinical consequences. Drugs 53(6):930–942PubMedCrossRefGoogle Scholar
  16. Conn HO, Leevy CM, Vlacevic ZR, Rodgers JB, Maddrey WC, Seef L (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72:573–583PubMedGoogle Scholar
  17. Cordóba J, Blei AT (1997) Treatment of hepatic encephalopathy. Am J Gastroenterol 92(9):1429–1439PubMedGoogle Scholar
  18. Dhiman RK, Sawhney MS, Chawla YK, Dhiman RK, Sawhney MS, Chawla YK (2000) Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 45(8):1549–1552PubMedCrossRefGoogle Scholar
  19. Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, Duseja A, Aggarwal R, Amarapurkar D, Sharma P, Madan K, Shah S, Seth AK, Gupta RK, Koshy A, Rai RR, Dilawari JB, Mishra SP, Acharya SK (2010) Indian National Association for Study of the Liver. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 25(6):1029–1041PubMedCrossRefGoogle Scholar
  20. Eltawil KM, Laryea M, Peltekian K, Molinari M (2012) Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 18(8):767–777PubMedCrossRefGoogle Scholar
  21. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy– definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721PubMedCrossRefGoogle Scholar
  22. Festi D, Mazzella G, Orsini M (1993) Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 54(5):598–609CrossRefGoogle Scholar
  23. Grandi M, Sacchetti C, Pederzoli S, Celani MF (1991) A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients. Minerva Gastroenterol Dietol 37(4):225–230PubMedGoogle Scholar
  24. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJC, Essink-bot MI, Hop WCJ, Schalm SW (1998) Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 28:45–49PubMedCrossRefGoogle Scholar
  25. Haüssinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S (2000) Hepatic encephalopathy in chronic liver desease: a clinical manifestation of astrocyte swelling and low grade cerebral edema. J Hepatol 32:1035–1038PubMedCrossRefGoogle Scholar
  26. Heredia D, Terés J, Orteu N, Rodés J (1988) Lactitol vs. lactulose in the treatment of chronic recurrent portal−systemic encephalopathy. J Hepatol 7(1):106–110PubMedCrossRefGoogle Scholar
  27. Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP (1997) Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 11(1):165–170PubMedCrossRefGoogle Scholar
  28. Jain L, Sharma BC, Sarin SK (2012) Serum endotoxin, inflammatory mediators and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. J Gastroenterol Hepatol 27(suppl 5):216Google Scholar
  29. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L (2008) Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta−analysis. Eur J Gastroenterol Hepatol 20(11):1064–1070PubMedCrossRefGoogle Scholar
  30. Lanthier PL, Morgan MY (1985) Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 26:415–420PubMedCrossRefGoogle Scholar
  31. Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52:737–741PubMedCrossRefGoogle Scholar
  32. Lockwood A, Yap E, Wong W (1991) Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 11:337–341PubMedCrossRefGoogle Scholar
  33. Loguercio C, Del Vecchio BC, Coltorti M (1987) Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 15(6):335–343PubMedGoogle Scholar
  34. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio BC, Coltorti M (1995) Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 23(1):39–46PubMedCrossRefGoogle Scholar
  35. Lunia MK, Sharma P, Sharma BC, Sarin SK (2012) A double blind randomised controlled trial comparing rifaximin plus lactulose with lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol 27(suppl 5):52Google Scholar
  36. Luo M, Li L, Lu CZ, Cao WK (2011) Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 23(12):1250–1257PubMedCrossRefGoogle Scholar
  37. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V (2003a) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38:51–58PubMedCrossRefGoogle Scholar
  38. Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A, Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group (2003b) J Hepatol 38(1):51–58PubMedCrossRefGoogle Scholar
  39. Massa P, Vallerino E, Dodero M (1993) Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 4:7–18Google Scholar
  40. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 9(11):CD008716Google Scholar
  41. Mittal VV, Sharma BC, Sharma P, Sarin SK (2011) A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 23(8):725–732PubMedCrossRefGoogle Scholar
  42. Mohammad RA, Regal RE, Alaniz C (2012) Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother 46(11):1559–63PubMedCrossRefGoogle Scholar
  43. Morgan MY, Hawley KE (1987) Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7(6):1278–1284PubMedCrossRefGoogle Scholar
  44. Morgan MY, Alonso M, Stanger LC (1989) Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 8(2):208–217PubMedCrossRefGoogle Scholar
  45. Mullen K, Prakash R (2010) Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 4(6):665–677PubMedCrossRefGoogle Scholar
  46. Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N (2012) Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 46(2):168–171PubMedCrossRefGoogle Scholar
  47. Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A (1981) Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 26:498–506PubMedCrossRefGoogle Scholar
  48. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM (2005) Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 46(3):399–407PubMedCrossRefGoogle Scholar
  49. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45(3):549–559PubMedCrossRefGoogle Scholar
  50. Riggio O, Balducci G, Ariosto F, Merli M, Pieche U, Pinto G, Tremiterra S, Ziparo V, Capocaccia L (1989) Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig Dis Sci 34(6):823–829PubMedCrossRefGoogle Scholar
  51. Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, Attili AF, Merli M (2005) Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 42:674–679PubMedCrossRefGoogle Scholar
  52. Riordan SM, Williams R (1997) Treatment of hepatic encephalopathy. N Engl J Med 337:473–479PubMedCrossRefGoogle Scholar
  53. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, García E, Aguilar-Reina J (2001) Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96:2718–2723PubMedGoogle Scholar
  54. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 34(8):853–61PubMedCrossRefGoogle Scholar
  55. Sharma P, Sharma BC (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(25):2423–2424PubMedCrossRefGoogle Scholar
  56. Sharma P, Sharma BC (2011) Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose. Saudi J Gastroenterol 17(2):138–141PubMedCrossRefGoogle Scholar
  57. Sharma P, Sharma BC (2012) Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Saudi J Gastroenterol 18(3):168–172PubMedCrossRefGoogle Scholar
  58. Sharma P, Sharma BC, Puri V, Sarin SK (2008) An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 20(6):506–511PubMedCrossRefGoogle Scholar
  59. Sharma P, Sharma BC, Sarin SK (2009a) Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 29(9):1365–1371PubMedCrossRefGoogle Scholar
  60. Sharma BC, Sharma P, Agrawal A, Sarin SK (2009b) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137:885–891PubMedCrossRefGoogle Scholar
  61. Sharma P, Sharma BC, Sarin SK (2010) Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol 22(5):526–531PubMedCrossRefGoogle Scholar
  62. Sharma P, Agrawal A, Sharma BC, Sarin SK (2011) Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 26(6):996–1003PubMedCrossRefGoogle Scholar
  63. Sharma P, Agrawal A, Sharma BC, Sarin SK (2012) Primary prophylaxis of hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 27(8):1329–1335PubMedCrossRefGoogle Scholar
  64. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 106(2):307–316PubMedCrossRefGoogle Scholar
  65. Simmons F, Goldstein H, Boyle JD (1970) A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 59:827–832PubMedGoogle Scholar
  66. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS (1992) Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16(1):138–144PubMedCrossRefGoogle Scholar
  67. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L (1987) Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 7:639–643PubMedCrossRefGoogle Scholar
  68. Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, Toda G, Kobayashi K, Muto Y, Tsujii T, Kawasaki H, Okita K, Tanikawa K, Fujiyama S, Shimada S (1997) Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 26(6):1410–1414PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of GastroenterologyG.B.Pant HospitalNew DelhiIndia

Personalised recommendations